SSSharon Saydah

Sharon Saydah

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Sharon Saydah has a total of 434 co-authors. Here are the top co-authors by number of shared publications:

  • Giuseppina Imperatore

    Division of Diabetes Translation, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Atlanta, GA

    12 shared publications
  • Edward W. Gregg

    School of Population Health, RCSI University of Medicine and Health Sciences, Dublin, Ireland

    8 shared publications
  • Leora R. Feldstein

    Coronavirus and Other Respiratory Viruses Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention , Atlanta, Georgia

    8 shared publications
  • Nicole D. Ford

    Coronavirus and Other Respiratory Viruses Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention (CDC), Atlanta, Georgia

    6 shared publications
  • Alexandra F. Dalton

    Coronavirus & Other Respiratory Viruses Division (CORVD), National Center for Immunization and Respiratory Diseases (NCIRD), Centers for Disease Control and Prevention (CDC), 1600 Clifton Rd., NE, Mailstop US1-1, Atlanta, GA 30329-4027, USA

    5 shared publications
  • Melissa Briggs-Hagen

    Coronavirus and Other Respiratory Viruses Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention , Atlanta, Georgia

    5 shared publications

Latest Publications

  • Open Access

    Long COVID prevalence among U.S. adults: A state-level ecological analysis of associations with SARS-CoV-2 incidence, COVID-19 hospitalization rates, COVID-19 vaccine coverage, and multimorbidity

    by Xinmeng Zhao, Li Deng, Nicole D. Ford, Sharon Saydah

    Background: Long COVID has emerged as a major public health concern in the United States, yet geographic variation in its prevalence remains poorly understood. This study examines how state-level differences in COVID-19 vaccination, SARS-CoV-2 infection burden, severity of acute COVID-19 (measured by hospitalization rates) and multimorbidity burden relate to adult Long COVID prevalence in the United States. Methods: We conducted an ecological analysis using data from the 2023 Behavioral Risk Factor Surveillance System (BRFSS), from which we estimated state-level prevalence of self-reported Long COVID among adults. These estimates were linked with publicly available data on SARS-CoV-2 incidence, COVID-19 hospitalizations, COVID-19 vaccine coverage, and a multimorbidity indicator (defined as ≥3 chronic conditions associated with increased risk of severe COVID-19, e.g., diabetes, obesity, chronic kidney disease). Multivariable linear regression models were used to assess the association between these factors and Long COVID prevalence, adjusting for state age and sex distributions. Rubin’s rules were applied to propagate the uncertainty in the estimates of Long COVID and COVID-19 vaccine coverage through regression analyses. Results: All examined factors—including SARS-CoV-2 incidence, COVID-19 hospitalization, COVID-19 vaccine coverage, and multimorbidity prevalence—varied by state. In univariable analyses, vaccine coverage and multimorbidity prevalence were significantly associated with Long COVID prevalence. In the multivariable model, vaccine coverage and SARS-CoV-2 incidence were significant; however, after accounting for uncertainty in Long COVID and vaccine coverage estimates, only higher vaccine coverage remained significantly associated with lower Long COVID prevalence. Conclusions: Higher State-level variation in COVID-19 vaccine coverage was consistently associated with lower adult Long COVID prevalence. These ecological findings support further investigation of vaccination and other state-level determinants of Long COVID burden and may inform population-level strategies for addressing Long COVID.

  • Open Access

    Retrospective cohort study measuring the disparities in post-COVID conditions among persons with disabilities: findings from primary care settings, 2019–22

    by Esther E Velasquez, Robert L Phillips, JoAnn M Thierry, Sharon Saydah, Emilia H Koumans, Ilia Rochlin, Linda Geng, David Rehkopf, Neil Kamdar

    Background and aims: This study compared the incidence of post-COVID conditions by pre-pandemic disability status within primary care. Methods: This retrospective observational study used electronic health record data to identify primary care patients with ≥1 visit during January 2018–December 2019 and ≥1 visit during May 2020–December 2022. Disability status was identified using diagnostic codes from January 2018 to December 2019. COVID-19 diagnosis was captured during April 2020–December 2022. Accelerated Failure Time models were used to assess time to incident circulatory, endocrine, neurological, and respiratory diagnoses at least 28 days post COVID-19. Results: Among patients aged ≥50 years, those with disabilities and COVID-19 had higher incidence and earlier onset of newly diagnosed circulatory [time ratio (TR) 0.70, 95% confidence interval (CI) 0.64–0.77], endocrine (TR 0.91, 95% CI 0.84–0.99), and neurological (TR 0.52, 95% CI 0.44–0.62), but not respiratory conditions during the post-COVID period as compared to patients with COVID-19 without disability. No associations were found among patients aged <50 years. Conclusion: Primary care patients with pre-existing disability experienced a higher incidence and earlier onset of post-COVID conditions than patients without disability.

  • Open Access

    Long COVID Prevalence among U.S. Adults: A State-level Ecological Analysis of the Contribution of COVID-19 Incidence, Severity of Acute Illness, COVID-19 Vaccination, and Chronic Conditions

    by Xinmeng Zhao, Li Deng, Nicole D. Ford, Sharon Saydah

    Background: Long COVID has emerged as a major public-health concern in the United States, yet geographic variation in its prevalence remains poorly understood. This study examines how state-level differences in COVID-19 vaccination, SARS-CoV-2 incidence, COVID-19 hospitalization, and chronic disease burden relate to adult Long COVID prevalence in the United States. Methods: We conducted an ecological analysis using data from the 2023 Behavioral Risk Factor Surveillance System (BRFSS), from which we estimated state-level prevalence of self-reported Long COVID among adults. These estimates were linked with publicly available data on SARS-CoV-2 incidence, COVID-19 hospitalizations, COVID-19 vaccine coverage, and a multimorbidity indicator (>= 3 chronic conditions e.g., diabetes, obesity, chronic kidney disease) associated with higher risk for severe SARS-CoV-2. Multivariable linear regression models were fitted to assess the contribution of each factor adjusted for age and sex distribution, incorporating Rubin’s rules to account for uncertainty in prevalence estimates. Results: All examined factors—including SARS-CoV-2 incidence, hospitalization rates, and multimorbidity, vaccine coverage—varied by state. When modeled simultaneously and adjusting for age and sex distribution, only COVID-19 vaccine coverage and SARS-CoV-2 incidence were significantly associated with Long COVID prevalence. COVID-19 vaccine coverage showed a strong protective association, while SARS-CoV-2 incidence showed a modest positive association. Multimorbidity and hospitalization rates were not independently associated with adjustment. Conclusions: State-level variation in Long COVID burden appears most strongly driven by COVID-19 vaccine coverage and SARS-CoV-2 incidence. Promoting COVID-19 vaccination remains essential to reduce long-term impacts from SARS-CoV-2 infections.

  • Open Access

    Editorial for epidemiology and infection, special issue on post-COVID condition

    by Sharon Saydah

    Long COVID presents a unique challenge to the research, medical, and public health communities. The challenge starts with the name used by researchers, clinicians, and patients (Long COVID, Post-COVID Conditions, or Post-acute Sequelae of SARS-CoV-2) and continues with the many symptoms and conditions included in the broad definition that can vary across studies and countries. Long COVID is complex and multifaceted, making it difficult to describe and define. Since Long COVID was first described by patients, the scientific and medical community has learned a great deal [1]. We have a better understanding of groups at increased risk for Long COVID [2]. Estimates on the number of people impacted by Long COVID vary by study population and study design, but recent estimates appear to be coalescing around 3%-5% among adults and 0.5%-2% among children [2-4], an estimated 65 million people globally [5, 6]. While the risk of developing Long COVID is low, the worldwide burden is quite high due to the large number of people who were and continue to be infected with SARS-CoV-2. Epidemiologic research is well poised to address many of the remaining questions surrounding Long COVID through observational studies that examine risk factors and phenotypes, explore potential biological mechanisms, and assess effectiveness of prevention and treatment. Each of the articles in this collection addresses a research gap and may help guide future efforts in unlocking the mysteries of Long COVID. This collection of articles on Long COVID advances the field by addressing many of the key questions and topics through original research, review of the state of the science, and recommendations for a path forward. One challenge in studying and understanding Long COVID is the need to prospectively follow individuals and monitor symptoms and conditions in the months and years following infection. Three of the articles in this collection do just that [7-9]. Beale and colleagues [7] present findings from Virus Watch, a prospective community cohort in England on the prevalence of Long COVID by SARS-CoV-2 variant period. The good news is that the occurrence of Long COVID following infection has declined since early in the pandemic. Unfortunately, this does not mean that Long COVID no longer occurs. While the numbers of people impacted going forward may decrease, there will still be people who experience long-term symptoms. In addition to longer term symptoms from SARS-CoV-2 infection, this study reports that people experiencing other acute respiratory infections (ARIs) may also experience longer term symptoms. As the authors point out, it will be important to continue to monitor longer term symptoms associated with infection by future SARS-CoV-2 variants and other respiratory viruses. Austhof and colleagues [8] report on persisting gastrointestinal (GI) symptoms and irritable bowel syndrome (IBS) following SARS-CoV-2 infections among a prospective cohort of adults living in Arizona. Gut immunology and the microbiome disruption are hypothesized to lead to ongoing GI symptoms possibly through viral persistence [10]. GI and IBS are not consistently reported by patients with Long COVID [11, 12] but can cause debilitating symptoms that impact quality of life. By prospectively following participants, Austhof and colleagues [8] are able to capture the ongoing impact and persistence of these symptoms. GI and IBS are symptoms and conditions that can lead to increased health care needs and may lend themselves to specific viral therapeutic targets [10]. One of the many challenges of Long COVID, as mentioned, is its clinical diagnosis and definition. This can lead to multiple treatment approaches to relieve symptoms. The goal of these treatments is typically to improve quality of life and reduce limitations on activities. The best way to measure this is by asking individuals about their symptoms and well-being. The study by Gorelik and colleagues [9] did that by asking adults, both those previously infected with SARS-CoV-2 and not infected, about their general well-being along with ongoing symptoms. They found that non-specific symptoms, such as fatigue, had the largest impact on well-being of participants. Given the broad definition of Long COVID, further refining the definition to include a measure of well-being could help guide clinicians as to what symptoms may require intervention or treatment to improve overall well-being of persons with Long COVID. In addition to prospective studies, cross-sectional studies can provide additional insights and a snapshot in time. Gerritzen et al. [13] furthers the understanding by describing phenotypes of Epidemiology and Infection

  • Open Access

    Comparative risk of post-acute sequelae following SARS-CoV-2 or influenza virus infection: A retrospective cohort study among United States adults

    by Joseph A. Lewnard, Debbie E. Malden, Vennis Hong, Jessica Skela, Leora R. Feldstein, Sharon Saydah, Iris Anne C. Reyes, Rulin Hechter, Lina S. Sy, Bradley K. Ackerson, et al.

    Background: Post-acute sequelae (PAS) of SARS-CoV-2 infection are well documented. However, it remains unclear whether such long-term health effects are unique to COVID-19, or also occur following other viral respiratory infections. Methods and findings: We undertook a retrospective cohort study of 74,738 COVID-19 cases and 18,790 influenza cases within the Kaiser Permanente Southern California healthcare system diagnosed between 1 September, 2022 and 31 December, 2023. Cases received care for index infections across a spectrum of clinical settings, spanning virtual ( n =  35,835; 38.3%), ambulatory ( n = 26,579; 28.4%), emergency department ( n =  23,388; 25.0%) and inpatient ( n = 7,726; 8.3%) facilities. We compared 180-day risk of PAS-related healthcare utilization among COVID-19 cases and influenza via adjusted hazard ratios (aHRs) weighted to account for cases’ index infection type and follow-up retention. Adjustment models addressed patients’ demographic characteristics, comorbidity profiles, prior healthcare utilization patterns, and index episode severity. Risk of PAS diagnoses in any clinical setting was only modestly higher among COVID-19 cases in comparison to influenza cases within 31−90 days after cases’ initial illness (aHR = 1.04 [95% confidence interval: 0.99, 1.09]; risk difference = 0.6 [–0.1, 1.2] cases per 100 person-months). This difference was attenuated by 91−180 days (aHR = 1.01 [0.97, 1.06]; risk difference = 0.4 [–0.1, 0.9] cases per 100 person-months). However, COVID-19 cases faced higher risk of severe PAS conditions requiring hospitalization (aHR = 1.31 [1.07, 1.59] and 1.24 [1.03, 1.49] within 31−90 and 91−180 days, respectively). This excess risk of severe PAS was concentrated among COVID-19 cases hospitalized during acute-phase illness, and was attenuated among cases who received antiviral treatment, who had up-to-date vaccination status prior to infection, or who did not require inpatient admission for acute-phase illness. As a limitation, analyses included only PAS resulting in healthcare utilization; patient-reported symptoms and quality-of-life measures were not captured. Conclusions: In this large, real-world cohort, individuals with non-severe acute respiratory illness caused by SARS-CoV-2 experienced only modestly greater risk of PAS in comparison to those whose illness was caused by influenza. However, COVID-19 cases hospitalized for their initial illness experienced greater risk of severe PAS necessitating inpatient care, and this difference persisted through 180 days of follow-up. Our findings challenge assumptions about the uniqueness of post-acute COVID-19 morbidity and suggest the long-term burden of influenza may be underrecognized.


  • Risk of Post-COVID-19 Conditions Among Adolescents and Adults Who Received Nirmatrelvir-Ritonavir for Acute COVID-19: A Retrospective Cohort Study

    by Alexandra F Dalton, Sarah Baca, Julia Raykin, Cria O Gregory, Tegan Boehmer, Emilia H Koumans, Priti R Patel, Pragna Patel, Sharon Saydah

    Background: Post-COVID-19 Conditions (PCC) potentially affect millions of people, but it is unclear whether treating acute COVID-19 with nirmatrelvir-ritonavir may reduce the risk of PCC. Methods: This is a retrospective cohort study using real-world, closed claims data to assess the relationship between nirmatrelvir-ritonavir and PCC by age group (12–17, 18–49, 50–64, ≥65 years). Eligible patients had a COVID-19 index date (positive laboratory test, ICD-10 diagnosis code, or nirmatrelvir-ritonavir prescription) from 1 April to 31 August 2022, in the outpatient, telehealth, or emergency department setting, and had a higher risk of severe COVID-19 based on age (≥50 years) or underlying risk factors. Treated patients (ie, received a nirmatrelvir-ritonavir prescription within ±5 days of index date) were matched 1:2 on age, sex, month of index date, and HHS region with untreated patients. PCC was defined by the presence of ≥1 of 45 new-onset symptoms or conditions recorded ≥60 days after index date. Results: Of the treated patients, 291 433 were matched to 582 866 untreated patients. Treatment with nirmatrelvir-ritonavir reduced PCC risk in adults 50–64 years (adjusted hazard ratio [aHR] 0.93, 95% confidence interval [CI] 0.92–0.95) and ≥65 years (aHR 0.88, 95% CI 0.87–0.90). Treatment had minimal effect among high-risk adults 18–49 years (aHR 0.98, 95% CI 0.97–0.99) and no effect among high-risk adolescents 12–17 years (aHR 1.06, 95% CI 0.66–1.13). Conclusions: Results using real-world data suggest a protective relationship between nirmatrelvir-ritonavir during acute illness and PCC risk among older adults, but not among adolescents. Consideration may be given to outpatient treatment of mild to moderate COVID-19 with nirmatrelvir-ritonavir to reduce the risk of severe disease and PCC.


  • Prevalence of Symptoms Associated With Long COVID Among Adolescents in the United States, Summer 2022

    by Deja L Edwards, Leora R Feldstein, Alexandra F Dalton, Nicole D Ford, Sharon H Saydah

    Background: Limited information is known about long COVID among adolescents. This study compared the risks associated with symptoms among adolescents who tested positive, were tested but never tested positive, or who were never tested for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Methods: Porter Novelli survey data were collected from adolescents (aged 12–17 years) from 31 May 31 through 6 July 2022. Respondents self-reported their SARS-CoV-2 test results and were classified accordingly by test status. Wald χ2 tests were used to determine whether demographic factors and characteristics related to symptoms differed by test status. Multivariable logistic regression models were used to estimate the odds of reporting (1) symptoms lasting 4 weeks or longer and (2) symptoms lasting 3 or more months by test status and SARS-CoV-2 variant period. Results: Data were collected from 784 respondents: 264 (34%) tested positive, 291 (37%) never tested positive, and 229 (29%) were never tested for SARS-CoV-2 infection. At least 1 symptom lasting ≥4 weeks was reported by 41% of the positive respondents, compared to 12% of negative respondents and 11% of never tested respondents (P < .05). The odds of reporting at least 1 symptom lasting ≥4 weeks did not vary by SARS-CoV-2 variant period. Adolescents who tested positive had increased odds of any neurological symptom lasting ≥3 months compared to negative adolescents. Conclusions: Our results demonstrate that adolescents who tested positive for SARS-CoV-2 were more likely to report at least 1 symptom lasting for at least 4 weeks. However, most of these symptoms appeared to have resolved within 3 months.

  • Open Access

    Incidence of long COVID among U.S. children and adults during the omicron era – Tracking Post-COVID Conditions (Track-PCC) network, 2022–2023

    by Brian E. Dixon, Katie S. Allen, Nicole Simmons, Jason Brinkley, Jennifer G. Andrews, Bari J. Dzomba, Marina O. Feiler, Resa M. Jones, Miguel Reina Ortiz, Vinita Sharma, et al.


  • Open Access

    Risk of Post-COVID Conditions among adolescents and adults who received nirmatrelvir-ritonavir for acute COVID-19: a retrospective cohort study

    by Alexandra F. Dalton, Sarah Baca, Julia Raykin, Cria O. Gregory, Tegan K Boehmer, Emilia H. Koumans, Priti R. Patel, Pragna Patel, Sharon Saydah

    Introduction: Post-COVID Conditions (PCC) potentially affect millions of people, but it is unclear whether treating acute COVID-19 with nirmatrelvir-ritonavir may reduce the risk of PCC. Methods: Retrospective cohort study using real-world, closed claims data to assess the relationship between nirmatrelvir-ritonavir and PCC by age group (12-17, 18-49, 50-64, ≥65 years). Eligible patients had a COVID-19 index date (positive laboratory test, ICD-10 diagnosis code, or nirmatrelvir-ritonavir prescription) from April 1 – August 31, 2022, in the outpatient, telehealth, or emergency department setting, and had a higher risk of severe COVID-19 based on age (≥50 years) or underlying risk factors. Treated patients (i.e., received a nirmatrelvir-ritonavir prescription within +/-5 days of index date) were matched 1:2 on age, sex, month of index date, and HHS region with untreated patients. PCC was defined by the presence of ≥1 of 45 new-onset symptoms or conditions recorded ≥60 days after index date. Results: 291,433 treated patients were matched to 582,866 untreated patients. Treatment with nirmatrelvir-ritonavir reduced PCC risk in adults 50-64 years (aHR 0.93, 95%CI 0.92-0.95) and ≥65 years (aHR 0.88, 95% CI 0.87-0.90). Treatment had minimal effect among high-risk adults 18-49 years (aHR 0.98, 95% CI 0.97-0.99), and no effect among high-risk adolescents 12-17 years (aHR 1.06, 95% CI 0.66-1.13). Conclusion: Results using real-world data suggest a protective relationship between nirmatrelvir-ritonavir during acute illness and PCC risk among older adults, but not among adolescents. Consideration may be given to outpatient treatment of mild to moderate COVID-19 with nirmatrelvir-ritonavir to reduce the risk of severe disease and PCC.